Metastatic Melanoma: Symptoms, Stages, Treatment

Metastatic Melanoma: Symptoms, Stages, Treatment

Metastatic Melanoma: Symptoms, Stages, Treatment
Shutterstock

Metastatic melanoma is an advanced form of melanoma. This subtype is one of the most dangerous types of skin cancer.

Melanoma begins in skin cells called melanocytes. Melanocytes produce melanin, the pigment that gives skin much of its color and provides some natural protection against ultraviolet radiation. These skin cells also produce moles, which are usually harmless but occasionally can become cancerous.

A melanoma can look like a mole. Melanoma is usually brown or black but can also be skin-colored, purple, blue, red, pink, or white.

To distinguish a normal mole from a potentially cancerous one, it’s important to perform regular skin self-exams and visit a dermatologist for skin checks on a regular schedule. Taking these precautions can be lifesaving.

What Is Metastatic Melanoma, and How Does It Differ From Melanoma?

Melanoma is any cancer that originates in the melanocytes, while metastatic melanoma is melanoma that spreads from the skin to other parts of the body, such as the lymph nodes, liver, lungs, bones, and brain.

When you learn about a melanoma at an early stage, while the cancer is still localized to the skin, treatment is generally straightforward (a doctor may simply cut out the tumor) and extremely effective, with a five-year survival rate of over 98 percent. Metastatic melanoma is much harder to treat and more life-threatening.

Overall, melanoma is responsible for more than 8,500 deaths in the United States each year, according to the National Cancer Institute.

Causes and Risk Factors for Metastatic Melanoma

Everyone — of every age, sex, race, and ethnicity — faces some level of melanoma risk, including the metastatic kind, but certain factors raise the odds. These include:

Ultraviolet (UV) Light Exposure: Whether it comes from the sun or from tanning beds, UV light is a very significant risk factor for melanoma. UV light damages the genes in melanocytes that control their growth. These mutated cells multiply with abnormal speed, sometimes forming cancerous tumors. A history of blistering sunburns, particularly during childhood or adolescence, is associated with increased melanoma risk.

Moles: Certain kinds of atypical moles known as dysplastic nevi, which can be larger than regular moles and have an abnormal shape or color, raise melanoma risk. People with an inherited condition called dysplastic nevus syndrome, which causes them to have many dysplastic nevi, are at very high risk of melanoma. Congenital melanocytic nevi — moles present at birth, especially very large ones — are another risk factor.

Fair Skin, Freckling, and Light Hair: Individuals with this complexion and coloring are at higher risk than others.

Family History of Melanoma: Around 10 percent of people with melanoma have a first-degree family member with the disease, such as a parent, sibling, or child.

Personal History of Melanoma or Other Skin Cancers: Having had melanoma raises the risk of getting it again. Having another type of skin cancer, such as basal or squamous cell skin cancer, is also a risk factor.

Having a Weakened Immune System: People with conditions that weaken the immune system, such as HIV, are at higher risk of developing melanoma. People taking medication to suppress the immune system after an organ transplant are also at higher risk.

Advanced Age: Older people are more likely to develop melanoma than younger people. But younger people aren’t free of risk. In fact, melanoma is one of the most common cancers in people younger than 30.

Gender: Among people in the United States older than 50 years old, men are at a higher risk of developing melanoma than women. Before age 50, women are at greater risk.

Xeroderma Pigmentosum: People with this rare inherited condition, characterized by sensitivity to UV light, have a very high melanoma risk.

What Are the Symptoms of Metastatic Melanoma?

Many people find out they have melanoma when symptoms prompt them to visit the doctor.

They may be concerned about a mole that is painful, itchy, or bleeding; that oozes or becomes scaly or lumpy; or that shows other signs of abnormality.

Doctors look for evidence of cancer in moles using what’s called the ABCDE method:

  • A: It is asymmetrical.
  • B: It has an irregular border.
  • C: It contains more than one color or is an unusual color.
  • D: Its diameter is unusually big, typically larger than 6 millimeters (mm), or ¼ inch.
  • E: It evolves, changing size, color, shape, or another characteristic.
These features can help identify suspicious lesions that a dermatologist should evaluate for melanoma. However, not all moles that meet points of the aforementioned criteria are melanomas; for example, a benign mole can be larger than 6 mm.

It’s possible that by the time a physician diagnoses melanoma on the skin, cancer cells have already spread to other parts of the body. Melanoma can also spread to a different part of the body after initial diagnosis and treatment.

People with metastatic melanoma may feel tired or unwell in general. They also may have specific symptoms based on where in the body the cancer cells have spread. (Some of these symptoms may have noncancerous causes.) Some parts of the body that metastatic cancer may affect include:

Lymph Nodes

Symptoms of melanoma that has spread to the lymph nodes may include:

  • Hard lumps under the skin
  • Difficulty swallowing (because of swollen lymph nodes in the neck)
  • Swelling in the neck or face (because of fluid buildup, a condition called lymphedema)

Lungs

Melanoma that has spread to the lungs can cause the following symptoms:

  • A persistent cough
  • Breathlessness
  • Ongoing chest infections
  • Coughing up blood
  • Fluid buildup between the chest wall and the lung

Liver

Metastatic melanoma in the liver can cause:

  • Discomfort or pain on the right side of the abdomen
  • Poor appetite and weight loss
  • Abdominal swelling
  • Yellowing of the skin and eyes (jaundice)
  • Itchy skin

Bone

The following symptoms may indicate metastatic melanoma:

  • Gnawing pain (caused by the breakdown of bone)
  • Worsening backache
  • Weaker bones that break more easily
  • Raised blood calcium, which can cause dehydration, confusion, abdominal pain, and constipation
  • Low levels of blood cells (which are produced in healthy bone but crowded out by cancer cells), which can cause bruising, bleeding, and an increased risk of infection

Brain

Melanoma that has spread to the brain can cause:

  • Headaches
  • Muscle weakness
  • Seizures
  • Personality or mood changes
  • Eyesight changes
  • Confusion

Diagnosis of Metastatic Melanoma

During a physical exam, a doctor will examine any suspicious moles or areas of the skin for signs of melanoma. They will also ask about possible risk factors.

The physician may also feel the lymph nodes under the skin in the neck, underarm, groin, or behind the knees near the abnormal area to check for any unusual enlargement.

Next, the doctor will likely collect a skin sample from the area in question to study under a microscope for cancer cells. If the lab results confirm melanoma, physicians may take samples of other tissues, too, to check for metastases. In this case, the doctor may start with the lymph nodes nearest the primary skin lesion.

Imaging tests, such as X-rays or computerized tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scans, can also look for enlarged lymph nodes or cancerous spots on the lungs, liver, and other body parts.

In rare cases, melanoma metastasizes quickly, before the original tumor on the skin is large enough to be detected. In these cases, physicians may first biopsy tissue from an area of metastasis to figure out what type of cancer the patient has.

For instance, a biopsy may determine that cancerous spots on the liver are not liver cancer (cancer that originates in liver cells) but skin melanoma that has metastasized.

This is critical information since different cancers respond to different treatments.

Stages of Metastatic Melanoma

Assigning a stage to a melanoma aims to describe how advanced the cancer is.

For patients with metastatic disease, determining the stage is crucial for identifying those who may be eligible for experimental treatments.

Stage 0

The melanoma is confined to the outermost layer of the skin; it has not spread.

Stage 1

The melanoma is no more than 2 mm thick and has not spread to lymph nodes or distant sites. Stage 1 is further divided according to tumor thickness and ulceration.

Stage 2

The melanoma has not spread to lymph nodes or distant sites but has features associated with higher risk, based primarily on its thickness and whether it is ulcerated, which is a sign of danger characterized by a breakdown of the skin over the tumor.

Stage 3

The melanoma has spread, sometimes as far as the nearest lymph nodes but no further. There are a number of stage 3 substages — 3A, 3B, 3C, and 3D — based on tumor thickness, whether the tumor is ulcerated, and how far the melanoma has spread.

Stage 4

The cancer can be any thickness and may or may not be ulcerated. It may or may not have spread to lymph nodes. However, the cancer has spread to distant lymph nodes or organs such as the lungs, liver, or brain.

Metastatic Melanoma Treatment Options

Treatment for metastatic melanoma often depends on the stage of the cancer. Chemotherapy, for example, which is medication designed to kill cancer cells, is typically not the first line of treatment for melanoma. According to the American Cancer Society, immunotherapy and targeted drugs are generally more effective forms of treatment.

 Chemotherapy may be used in advanced cases when other approaches have not worked.

Immunotherapy

Immunotherapy uses the body’s own powerful immune system to treat metastatic melanoma.

One especially promising form of immunotherapy is called immune checkpoint blockade therapy, or immune checkpoint inhibitor therapy. These drugs gained U.S. Food and Drug Administration (FDA) approval in 2011,

 and research backs that they are extending the lives of people with stage 3 and stage 4 melanomas. Two forms of immunotherapy drugs, pembrolizumab (Keytruda) and nivolumab (Opdivo), both approved by the FDA in 2014, have become frontline medications for metastatic melanoma. Both work by blocking the action of a molecule called PD-1 (programmed death-1), which normally keeps the immune system’s T cells in check. No longer held back by PD-1, the T cells are let loose to attack cancer.
In 2015, former President Jimmy Carter credited a combination of surgery, radiation, and Keytruda with sending his cancer into full remission after metastatic melanoma had spread to his brain.

 In 2021, the FDA approved Keytruda to treat high-risk, stage 2 melanoma.

In 2024, the Annals of Oncology published a 10-year follow-up study to landmark research evaluating pembrolizumab as a treatment for advanced melanoma. It found that the drug was more effective at improving survival rates than another form of immunotherapy, ipilimumab (Yervoy). The results support pembrolizumab’s status as the standard of care for advanced melanoma.

Another viable approach for using immunotherapy to treat metastatic melanoma is to combine checkpoint blockade therapies. Doing so may increase the chance of serious side effects, yet researchers are finding that this strategy can improve survival rates to such an extent that it’s a valuable option for some patients, despite the risks involved.

A study of patients with advanced melanoma who were treated with both nivolumab and ipilimumab (Yervoy) found that after 10 years, the median overall survival for patients on the combined treatment was about six years, while the median overall survival for taking nivolumab alone was about three years and ipilimumab alone was about 1.5 years. Another combination immunotherapy, of nivolumab and relatlimab, has shown promising survival rates for patients with metastatic cancer compared with nivolumab alone.

The FDA recently approved the combination of vusolimogene oderparepvec-wtpg (Tudriqev) and nivolumab to treat unresectable advanced cutaneous melanoma with disease progression that includes a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. Anti-PD-1 refractory melanoma is an advanced form that doesn’t respond to immunotherapy. Rather than a form of immunotherapy, Tudriqev is a genetically modified oncolytic viral therapy. In a clinical trial, 1 in 4 patients responded to the combination.

Targeted Therapies

A new generation of melanoma therapies works by targeting mutations (DNA defects) in melanoma cells, shrinking tumors or slowing their growth.

About one-half of all melanomas have mutations (DNA defects) in the BRAF gene that are responsible for out-of-control cellular growth.

Several medicines targeting this mutation, called BRAF inhibitors, are FDA-approved, with research supporting them as a second line of treatment after immunotherapy.

A combination of these drugs with other drugs aimed at the related MEK mutation to treat metastatic melanoma with the BRAF mutation.

These three combination therapies are now approved:

  • dabrafenib (Tafinlar) and trametinib (Mekinist)
  • vemurafenib (Zelboraf) and cobimetinib (Cotellic)
  • encorafenib (Braftovi) and binimetinib (Mektovi)

Prognosis for Metastatic Melanoma

Until recent years, a metastatic melanoma prognosis gave patients very little reason to hope.

But since 2011, physicians have had access to remarkable new drugs that are helping many patients live significantly longer.

Many patients with metastatic melanoma are responding to the new treatments, extending their lives by months and years. Some are even going into long-term remission.

According to the American Cancer Society, the five-year survival rate is about 76 percent for regional melanoma (spread to nearby lymph nodes) and about 36 percent for distant (spread to further parts of the body). But those numbers are expected to rise now that doctors are treating more patients with newly approved drugs.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Melanoma Overview. Skin Cancer Foundation. March 2026.
  2. Survival Rates for Melanoma Skin Cancer. American Cancer Society. August 12, 2026.
  3. Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute.
  4. Melanoma Risk Factors. Skin Cancer Foundation. June 2021.
  5. Baigrie D, Tanner LS. Dysplastic Nevi. StatPearls. October 24, 2022.
  6. Large congenital melanocytic nevus. Genetic and Rare Diseases Information Center. June 2026.
  7. Wang S et al. Natural hair color and skin cancers: A two-sample Mendelian randomization study. Gene. January 30, 2024.
  8. Causes, Risk Factors, and Prevention of Melanoma Skin Cancer. American Cancer Society. August 12, 2026.
  9. Melanoma Warning Signs. Skin Cancer Foundation. March 2026.
  10. Symptoms of advanced melanoma skin cancer. Cancer Research UK. January 30, 2025.
  11. Tests for Melanoma Skin Cancer. American Cancer Society. August 12, 2026.
  12. Melanoma Treatment (PDQ®)–Patient Version. National Cancer Institute. May 16, 2025.
  13. Stages of Melanoma Skin Cancer. American Cancer Society. August 12, 2026.
  14. Chemotherapy for Melanoma Skin Cancer. American Cancer Society. August 12, 2026.
  15. Lee JB et al. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network. February 14, 2022.
  16. Jimmy Carter’s Melanoma Appears to Respond to Immunotherapy. American Association for Cancer Research.
  17. Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning. National Cancer Institute. October 13, 2021.
  18. Long GV et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of Oncology. December 2024.
  19. Wolchok JD et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. January 2, 2025.
  20. Wolchok JD et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England Journal of Medicine. January 6, 2022.
  21. FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma. U.S. Food and Drug Administration. August 6, 2026.
  22. Ellebaek E et al. Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study. EJC Skin Cancer. 2026.
  23. Understanding Melanoma Treatment. Skin Cancer Foundation. August 2026.

Blair Murphy-Rose, MD

Medical Reviewer

Blair Murphy-Rose, MD, is a board-certified dermatologist in New York City and the founder of Skincare Junkie. She is an accomplished cosmetic, medical, and surgical dermatologist,...

Pam-Kaufman-article

Pamela Kaufman

Author

Pamela Kaufman assigns and edits stories about infectious diseases and general health topics and strategizes on news coverage. She began her journalism career as a junior editor on...